Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Landos Biopharma (LABP) Stock Forecast & Price Target

Landos Biopharma logo
Get the Latest News and Ratings for LABP and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Landos Biopharma and its competitors.

Sign Up

LABP Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$20.42$20.42$20.42N/A
Forecasted Upside-10.95% Downside-10.95% Downside-10.95% DownsideN/A
Consensus Rating
Hold
Hold
Hold
Sell

LABP Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LABP Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Landos Biopharma Stock vs. The Competition

TypeLandos BiopharmaMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside-10.95% Downside27,212.41% Upside8.86% Upside
News Sentiment Rating
Neutral News

See Recent LABP News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/1/2024HC Wainwright
2 of 5 stars
R. Selvaraju
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$50.00 ➝ $20.42-4.93%
1/6/2023Jefferies Financial Group
2 of 5 stars
 DowngradeHold ➝ Underperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:41 PM ET.


LABP Forecast - Frequently Asked Questions

According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for Landos Biopharma is $20.42, with a high forecast of $20.42 and a low forecast of $20.42.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Landos Biopharma in the last twelve months. There is currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" LABP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LABP, but not buy additional shares or sell existing shares.

According to analysts, Landos Biopharma's stock has a predicted downside of -10.95% based on their 12-month stock forecasts.

Analysts like Landos Biopharma less than other "medical" companies. The consensus rating for Landos Biopharma is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how LABP compares to other companies.


This page (NASDAQ:LABP) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners